Assessing preferences for HIV pre-exposure prophylaxis (PrEP) delivery services via online pharmacies in Kenya: protocol for a discrete choice experiment.

HEALTH SERVICES ADMINISTRATION & MANAGEMENT HIV & AIDS Health economics International health services Public health Telemedicine

Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
03 04 2023
Historique:
medline: 5 4 2023
entrez: 3 4 2023
pubmed: 4 4 2023
Statut: epublish

Résumé

Pre-exposure prophylaxis (PrEP) is highly effective at preventing HIV acquisition, but coverage remains low in high prevalence settings. Initiating and continuing PrEP via online pharmacies is a promising strategy to expand PrEP uptake but little is known about user preferences for this strategy. We describe methods for a discrete choice experiment (DCE) to assess preferences for PrEP delivery from an online pharmacy. This cross-sectional study is conducted in Nairobi, Kenya, in partnership with MYDAWA, a private online pharmacy retailer with a planned sample size of >400 participants. Eligibility criteria are: ≥18 years, not known HIV-positive and interested in PrEP. Initial DCE attributes and levels were developed via literature review and stakeholder meetings. We conducted cognitive interviews to assess participant understanding of the DCE survey and refined the design. The final DCE used a D-efficient design and contained four attributes: PrEP eligibility assessment, HIV test type, clinical consultation type and user support options. Participants are presented with eight scenarios consisting of two hypothetical PrEP delivery services. The survey was piloted among 20 participants before being advertised on the MYDAWA website on pages displaying products indicating HIV risk (eg, HIV self-test kits). Interested participants call a study number and those screened eligible meet a research assistant in a convenient location to complete the survey. The DCE will be analysed using a conditional logit model to assess average preferences and mixed logit and latent class models to evaluate preference heterogeneity among subgroups. This study was approved by the University of Washington Human Research Ethics Committee (STUDY00014011), the Kenya Medical Research Institute, Nairobi County (EOP/NMS/HS/128) and the Scientific and Ethics Review Unit in Kenya (KEMRI/RES/7/3/1). Participation in the DCE is voluntary and subject to completion of an electronic informed consent. Findings will be shared at international conferences and peer-reviewed publications, and via engagement meetings with stakeholders.

Identifiants

pubmed: 37012008
pii: bmjopen-2022-069195
doi: 10.1136/bmjopen-2022-069195
pmc: PMC10083853
doi:

Substances chimiques

Anti-HIV Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e069195

Subventions

Organisme : NIMH NIH HHS
ID : K01 MH122326
Pays : United States
Organisme : NIMH NIH HHS
ID : K99 MH121166
Pays : United States
Organisme : NIMH NIH HHS
ID : R00 MH121166
Pays : United States

Informations de copyright

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

BMC Health Serv Res. 2020 Nov 12;20(1):1034
pubmed: 33176785
BMJ Open. 2020 Nov 6;10(11):e039313
pubmed: 33158826
Appl Health Econ Health Policy. 2003;2(4):213-24
pubmed: 15119540
Value Health. 2011 Jun;14(4):403-13
pubmed: 21669364
Curr HIV/AIDS Rep. 2019 Feb;16(1):113-119
pubmed: 30701404
Curr Opin HIV AIDS. 2019 Sep;14(5):354-365
pubmed: 31343457
Pharmacoeconomics. 2008;26(8):661-77
pubmed: 18620460
Value Health. 2013 Jan-Feb;16(1):3-13
pubmed: 23337210
J Int AIDS Soc. 2016 Dec 12;19(1):21134
pubmed: 27964776
EClinicalMedicine. 2022 Jul 09;51:101507
pubmed: 35844771
Patient. 2015 Oct;8(5):373-84
pubmed: 25726010
J Int AIDS Soc. 2020 Jun;23 Suppl 3:e25537
pubmed: 32602658
PLoS One. 2017 Jan 26;12(1):e0170868
pubmed: 28125699
Curr HIV/AIDS Rep. 2020 Oct;17(5):467-477
pubmed: 32860150
Lancet HIV. 2020 Apr;7(4):e249-e261
pubmed: 32087152
Value Health. 2016 Jun;19(4):300-15
pubmed: 27325321
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
PLoS Med. 2018 Aug 13;15(8):e1002636
pubmed: 30102693
Med Decis Making. 2018 Jan;38(1):120-133
pubmed: 28863752
Trop Med Int Health. 2020 Sep;25(9):1155-1165
pubmed: 32609932
Med Decis Making. 2019 Aug;39(6):681-692
pubmed: 31354031
BMJ Open. 2016 Jun 27;6(6):e010682
pubmed: 27354071
Value Health. 2010 Dec;13(8):1046-55
pubmed: 20825620
Patient. 2021 Mar;14(2):151-174
pubmed: 33319339
BMJ Open. 2021 Sep 27;11(9):e049011
pubmed: 34580095
JMIR Mhealth Uhealth. 2020 Oct 2;8(10):e18351
pubmed: 33006562
Pan Afr Med J. 2020 May 20;35(Suppl 2):43
pubmed: 33623568
Health Policy Plan. 2002 Jun;17(2):187-95
pubmed: 12000779
PLoS One. 2012;7(5):e36797
pubmed: 22574226
BMC Health Serv Res. 2014 May 21;14:231
pubmed: 24886646
Int J Med Inform. 2021 Jul;151:104467
pubmed: 33915421
PLoS One. 2014 Mar 18;9(3):e92100
pubmed: 24643047

Auteurs

Yilin Chen (Y)

The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, University of Washington, Seattle, Washington, USA ylchen95@uw.edu.

Enrique M Saldarriaga (EM)

The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, University of Washington, Seattle, Washington, USA.

Michalina A Montano (MA)

Vaccine and Infectious Diseases Division (VIDD), Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Department of Global Health, University of Washington, Seattle, Washington, USA.

Kenneth Ngure (K)

School of Public Health, Jomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya.

Nicholas Thuo (N)

Partners in Health Research and Development, Center for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya.

Catherine Kiptinness (C)

Partners in Health Research and Development, Center for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya.

Maeve Rafferty (M)

MYDAWA, Nairobi, Kenya.

Fern Terris-Prestholt (F)

Department of Global Health and Development, London School of Hygiene and Tropical Medicine Faculty of Public Health and Policy, London, UK.

Andy Stergachis (A)

The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, University of Washington, Seattle, Washington, USA.
Department of Global Health, University of Washington, Seattle, Washington, USA.

Melissa Latigo Mugambi (ML)

Department of Global Health, University of Washington, Seattle, Washington, USA.

Katrina F Ortblad (KF)

Public Health Science Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.

Monisha Sharma (M)

Department of Global Health, University of Washington, Seattle, Washington, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH